Search Results

Policy

USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, announced the U.S. Department of Agriculture approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza.

June 25, 2024

·

6 min read

Deals

Merck Animal Health to Acquire Elanco’s Aqua Business

Merck Animal Health announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species.

February 5, 2024

·

7 min read

Pharm Country

Merck Animal Health’s Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association.

January 15, 2024

·

12 min read

Press Releases

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

September 25, 2024

·

5 min read

Vaccines

CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

October 24, 2024

·

2 min read

·

Tristan Manalac

Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company

Earnings

Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results

Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.

October 31, 2024

·

2 min read

·

Tristan Manalac

Pictured: Infant in the hospital wearing a ventila

RSV

Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory syncytial virus-associated infections in infants, while Pfizer’s RSV vaccine Abrysvo showed 90% effectiveness at preventing the most severe RSV cases in adults 60 years and older.

October 18, 2024

·

2 min read

·

Tristan Manalac

Pictured: Merck building and sign in Silicon Valley

Cancer

Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.

September 25, 2024

·

2 min read

·

Tristan Manalac

BioMidwest

ByoPlanet and Merck Animal Health Announce Partnership with USEF

ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc. and Merck Animal Health are proud to announce a groundbreaking partnership with The United States Equestrian Federation to advance animal health through innovative products and technologies.

May 23, 2023

·

5 min read

Business

Plandai Subsidiary ByoPlanet Announces Strategic Distribution Agreement with Merck Animal Health

ByoPlanet is excited to announce the establishment of a comprehensive one-year distribution agreement with Merck Animal Health, a global leader in animal health solutions and a division of Merck & Co.

May 19, 2023

·

5 min read